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possible scenarios. CONCLUSIONS: Conjoint analysis can be
used to assess the preferences of patients with schizophrenia,
and such preferences appear valid and relatively consistent.
Although further validation and reﬁnement is needed, our
results indicate that conjoint analysis is a feasible and beneﬁcial
method for measuring patient preferences among patients with
schizophrenia.
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OBJECTIVES: Different instruments are available to assess
health in individuals with psychotic illness. We aimed to identify
the complementary value of some different instruments to assess
health and health changes in schizophrenic patients.
METHODS: We analysed data from a naturalistic, prospective
cohort study, called COMETA, which involved 637 patients aged
18–40 years, 65.0% male, with schizophrenia (86.5%) or schizo-
phreniform disorder (13.5%), enrolled in 2006–2007 and fol-
lowed up to 52 weeks. Symptoms and functional changes were
assessed with the physicians’ rated scales Positive-And-Negative-
Syndrome-Scale (PANSS), Global-Assessment-of-Functioning
(GAF), Clinical-Global-Impression-Severity (CGI-S). The physi-
cians’ opinion was asked to assess compliance toward antipsy-
chotic treatment. Patients reported their attitude toward
treatment with the Drug-Attitude-Inventory (DAI-30). QoL was
assessed with EQ-5D and SF-36. We investigated whether rela-
tionships exist between scores obtained from the different scales.
RESULTS: At enrolment, signiﬁcant correlations were found
between PANSS, GAF, CGI-S scores (r, absolute value = 0.674–
0.766). Every QoL score signiﬁcantly correlated each other (r =
0.360–0.582). Correlations were lower between QoL and clinical
scores (0.189–0.393). Low correlations were estimated between
QoL scores and physicians’ reported compliance (r = 0.113–
0.282) or DAI-30 score (0.142–0.274). Each instrument showed
an average improvement in the patients’ condition after 52
weeks. However, scarce correlation was found between clini-
cians’ and patients’ reported changes. CONCLUSIONS: Both
clinicians’ and patients’ reported outcomes are necessary for a
complete evaluation of schizophrenic patients’ health. Further-
more, its brevity, and its immediateness of data reading and
interpretation are reasons for considering its introduction into
the physicians’ armamentarium for practice.
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OBJECTIVES: To present 2-year results on treatments prescribed
and their impact on quality of life (QoL) and clinical severity of
children with Attention Deﬁcit / Hyperactivity Disorder (ADHD).
METHODS:ADORE is a 2-year, prospective, international obser-
vational study in ADHD. Treatments were classiﬁed as pharma-
cotherapy, psychotherapy, pharmacotherapy and psychotherapy
combination, other, and none. As patients were allowed to change
treatment, different patients may be included in each group at
different endpoints. QoLwasmeasuredwith the ChildHealth and
Illness Proﬁle (CHIP-CE). Clinical ADHD outcomes were mea-
sured with ADHD-Rating scale parent version (ADHD-RS), CGI-
Severity scale, Children’s Global Assessment Scale (CGAS) and
Strengths and Difﬁculties Questionnaire (SDQ). Changes in out-
comes presented hereafter were estimated on all patients followed
2 years and having at least baseline and 24 months visits.
RESULTS: Among 255 French patients eligible for analysis, mean
age (SD) 8.8 years (2.3), 87.5%male, 137 (53.7%) were followed
over 24 months. Treatments were respectively at baseline and 2
years: pharmacotherapy 23.0% & 29.1%, combination
pharmacotherapy/psychotherapy 36.6% & 47.0%, psycho-
therapy 27.2% & 12.7%, other treatment 4.7% & 3.0% and
none 8.5% & 8.2%. Between baseline and 2 years, CHIP-CE
quality of life improved: mean change from baseline was +5.7
(12.9) for satisfaction, +8.6 (11.8) for achievement, +13.4 (13.0)
for risk avoidance, +5.2 (12.4) for resilience and +5.2 (9.6) for
comfort. Between baseline and 2 years, mean ADHD-RS change
was -18.3 (9.9) leading to a ﬁnal score of 21.4 (10.7) at 2 years.
CGAS mean change was +15.8 (15.5) leading to a ﬁnal score of
67.1 (16.2). Mean CGI-S change was -1.5 (1.4) leading to a ﬁnal
score of 3.2 (1.3). Rate of patients with 31 comorbidity decreased
from 76.5% to 54.0% and severity of comorbidities also
decreased. CONCLUSIONS: After 2 years, French patients suf-
fering from ADHD symptoms enrolled in this study beneﬁted
from improvement of QoL and clinical severity. Interpretation is
difﬁcult due to patients changing treatments over the study.
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OBJECTIVES: To explore the association between Sad Blue
Depressed Days (SBDD), health-related quality of life, and health
behaviors among women in a university community in Venezu-
ela. METHODS: A random sample of 71 women ranging in age
from 18 to 72 years was surveyed using a written questionnaire.
The questionnaire included the SBDD question from the Behav-
ioral Risk Factor Surveillance System (BRFSS) and the SF-36
Health Survey. The associations among SBDD, SF-36, demo-
graphics, and health behaviors were estimated computing
Pearson correlation coefﬁcients for continuous variables and
Kendall’s tau for categorical variables. RESULTS: The sample
had a mean age of 31.98 years (s.d.13.86). The prevalence of
alcohol consumption during the previous month was 63.4% and
for smoking it was 16.9%. About 60% of the sample reported no
exercising regularly during the previous month. Most of the
respondents reported sleeping problems. Respondents reported a
mean of 4.33 (s.d.7.89) SBDD in the previous 30 days. Young
women aged 18–24 years reported the highest number of SBDD
(7.51, s.d. 9.80), whereas older women aged 45+ reported the
lowest number (1.50, s.d. 3.86). About 80% of respondents
reported one or more SBDD including 18.3% who reported 14
or more SBDD. The SF-36 showed good internal consistency
reliability. Respondents scored higher in Physical Functioning
(91.76, s.d.10.53) and lower in Vitality (62.25, s.d. 20.07).
SBDD correlated signiﬁcantly with all SF-36 domains, except
Physical Functioning and Bodily Pain. SBDD was associated to
lack of regular exercise, sleeping problems, and poor perception
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of emotional support. CONCLUSIONS: This exploratory study
supports the construct validity of the SBDD measure because
SBDD was associated with SF-36 domains in expected ways.
SBDD was associated with certain predictors of future health
status, including health behaviors such as regular exercise. SBDD
could be use as a community indicator to assess the burden of
mental distress in women in Venezuela.
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OBJECTIVES: To assess health-related quality of life (QoL) of
married, working women with children (working-moms) faced
with psychosocial stress (known as superwoman syndrome).
METHODS: A total of 200 working-moms (aged 40.2  5.3)
were recruited randomly by telephone, and a questionnaire was
administered to classify types of superwomen syndrome: self-
reliance type (ST), conﬂict type (CT), and additive type (AT). To
compare, a community samples of aged group (n = 80, aged 70.0
 5.9) were recruited at a local community center. We measured
QoL using SF-36v2 for both groups. RESULTS: As expected
younger working-moms reported signiﬁcantly higher physical
function (PF: 79.7 18.7 vs. 71.9 21.9; p = .0031) and mental
health (MH: 49.2  15.3 vs. 41.0  14.8; p < .0001). On the
contrary role-physical (RP: 78.9  23.6 vs. 80.5  22.5) and
role-emotional (RE: 77.2  25.0 vs. 83.2  24.0) scores were
lower than aged. Additionally, social functioning (SF) was signiﬁ-
cantly lower in working-moms (p < .0003). Further by types, most
physical-related scales of ST group (n = 10) were signiﬁcantly
higher (all p’s < 0.0025), whereas vitality (VT) and MH were
lower than aged.Majority of working-momswere classiﬁed as CT
group (n = 169). They reported the same QoL patterns as total
samples. Notably, AT group (n = 21) reported only MH (62.9 
13.8 vs. 41.0  14.8; p < 0.0001) was signiﬁcantly higher than
aged, and rest were either similar (PF, VT), or signiﬁcantly lower
than aged (RP: 62.8  24.6 vs. 80.5  22.5, RE: 55.1  26.6 vs.
83.2  24.0; all p’s < 0.002). CONCLUSIONS: Most working-
moms reported higher functioning and well-being, but in fact they
were limited in playing roles due to physical andmental problems.
It is suspected that they are denying and suppressing their various
health problems. Particularly, additive group report they are in
well-being, but the study showed they are deﬁnitely not. They even
may develop mentally and physically-related diseases in the near
future. Therefore, a cohort study is urgent for working, married
women with children in Korea.
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OBJECTIVES: Develop a cross-cultural translation, Swedish to
Spanish, of TOOL questionnaire—a previously validated instru-
ment to assess the impact of adverse effects (AE) on the health
utilities and health related quality of life (HRQoL) in patients
with schizophrenia and bipolar disorder. METHODS: TOOL
questionnaire has 8 attributes and 4 levels per domain (Likert
scale). These domains are mood (anxiety and depression), func-
tion capabilities, and AE frequently associated with antipsy-
chotic drugs (fatigue-weakness, weight gain, stiffness-tremor,
physical restlessness, sexual dysfunction, and vertigo-nausea).
Firstly, 4 independent translators (3 Spanish and 1 Swedish)
carried out the forward-backward translations of the original
TOOL questionnaire. Next, draft version was reviewed by an
experts panel (5 psychiatrists & 1 GP specialized in HRQoL)
and tested in 40 stable patients (20 schizophrenic & 20
bipolar). Regarding patients’ responses, comprehension and
importance (C/I) of each item were evaluated by using a Likert
scale ranging from 0 (lowest level of C/I) to 4 (highest level of
C/I). Furthermore, feasibility and internal consistency were pre-
liminary analyzed. RESULTS: According to experts’ criteria 3
items should be modiﬁed to facilitate comprehension: mood,
physical restlessness and vertigo-nausea. However, C/I of items
mean scores were respectively: mood (3.50/2.37); function capa-
bilities (2.58/2.03); fatigue-weakness (3.58/2.55); weight gain-
(3.75/2.87); stiffness-tremor (3.65/2.61); restlessness (3.37/
2.62); sexual dysfunction (3.39/2.51) and vertigo-nausea (3.56/
2.44). Furthermore, only 2 patients (5%) were unable to
complete this questionnaire. Internal consistency was high
(Cronbach a = 0.87) and neither item ceiling nor ﬂoor effects
were found in patients responses. Finally, the Spanish version of
the TOOL questionnaire was reached by consensus. CONCLU-
SIONS: The Swedish TOOL questionaire was culturally
adapted into Spanish. Psychometric analyses are needed to vali-
date this HRQoL measure in Spain. Moreover, a multtiatribute
utility fuction should be estimated to evaluate AE by using a
patients’ centered perspective.
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OBJECTIVES: 1) To develop a linguistically validated version of
the DMI-18 in Castilian; 2) to evaluate its sensitivity and speci-
ﬁcity as a screening tool for depression in a sample of patients
with an organic illness attending the General Hospital of
Galdakao—Usansolo; and 3) to compare its screening qualities
with the ones of the most used screening tools, such as the
Hospital and Anxiety Depression Scale (HADS), the Beck
Depression Inventory Fast Screen (BDI-FS) and the Patient
Health Questionnaire-9 (PHQ-9). METHODS: The DMI-18 was
validated linguistically into Castilian using the translation—
backtranslation method recommended by Acquadro, Conway,
Giroudet, and Mear, (2004). Researchers interviewed somatic
patients (n = 11) and experts in depression (n = 3) to detect
possible understanding difﬁculties in the DMI-18 questions. Dr.
Parker, original author of the DMI-18, collaborated during the
translation process. The sample was composed by 156 outpa-
tients and inpatients that were attending some service of the
Hospital. Patients completed the DMI-18, HADS, BDI-FS and
the PHQ-9. Immediately afterwards a mental health clinician
interviewed patients individually using a psychiatric semistruc-
tured interview (PRIME-MD) to state whether the patient pre-
sented or not an affective disorder. The resulting diagnoses
coming from the self application of the screening tests were
compared against the clinical assessments made by the expert in
mental health. These data were used to calculate the sensitivity
and the speciﬁcity of the DMI-18, and of the competing screening
instruments. RESULTS: Using the clinicians valuation as the gold
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